What is the most recent earnings date for ALPN stock?
ALPINE IMMUNE SCIENCES INC (ALPN) last reported earnings on 5/9/2024.
ALPINE IMMUNE SCIENCES INC (ALPN) Earnings History & Surprises
NASDAQ:ALPN • US02083G1004
Current stock price
64.97 USD
+0.01 (+0.02%)
At close:
64.99 USD
+0.02 (+0.03%)
After Hours:
ALPN Earnings overview
Past quarterly earnings results for ALPINE IMMUNE SCIENCES INC (ALPN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Aug 12, 2024
- Period
- Q2 / 2024
- EPS Estimate
- -$0.41
- Revenue Estimate
- 3.559M
Last Reported
Most Recent- Release Date
- May 9, 2024
- Period
- Q1 / 2024
- EPS Reported
- -$0.28
- EPS Surprise
- 33.62%
- Revenue Surprise
- 96.10%
Beat Rate
Last 8 Quarters 56%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2024 | -0.28 | -0.42 | 33.62% | - | 7.032M | 3.586M | 96.10% | -25.09% |
| Q4 2023 | 0.12 | -0.34 | 135.04% | 129.27% | 30.853M | 9.286M | 232.25% | 1,009.82% |
| Q3 2023 | -0.24 | -0.34 | 29.64% | 42.86% | 10.043M | 7.394M | 35.83% | 19.99% |
| Q2 2023 | -0.27 | -0.38 | 29.29% | 55.00% | 8.593M | 9.027M | -4.81% | 62.44% |
| Q1 2023 | -0.28 | -0.38 | 25.93% | -12.00% | 9.387M | 8.772M | 7.01% | -31.13% |
| Q4 2022 | -0.41 | -0.27 | -49.99% | 21.15% | 2.78M | 11.184M | -75.14% | -38.63% |
| Q3 2022 | -0.42 | -0.10 | -301.72% | 23.64% | 8.37M | 19.059M | -56.08% | -1.76% |
| Q2 2022 | -0.60 | -0.40 | -49.87% | -30.43% | 5.29M | 10.245M | -48.37% | -26.43% |
| Q1 2022 | -0.25 | -0.19 | -30.72% | 44.44% | 13.63M | 16.589M | -17.84% | 325.94% |
| Q4 2021 | -0.52 | -0.31 | -67.15% | -92.59% | 4.53M | 14.249M | -68.21% | -19.68% |
| Q3 2021 | -0.55 | 0.01 | -10,884.31% | -96.43% | 8.52M | 21.611M | -60.58% | 346.07% |
| Q2 2021 | -0.46 | -0.40 | -13.88% | 13.21% | 7.19M | 6.606M | 8.84% | 942.03% |
| Q1 2021 | -0.45 | -0.36 | -23.69% | -50.00% | 3.2M | 5.671M | -43.57% | 193.58% |
| Q4 2020 | -0.27 | -0.32 | 15.07% | - | 5.64M | 2.639M | 113.72% | - |
| Q3 2020 | -0.28 | -0.24 | -18.07% | - | 1.91M | 16.399M | -88.35% | - |
| Q2 2020 | -0.53 | 0.55 | -197.12% | - | 690K | 16.93M | -95.92% | - |
| Q1 2020 | -0.30 | -0.48 | 37.42% | - | 1.09M | 384.203K | 183.70% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
56.90%
Max EPS beat (4)
135.04%
Min EPS beat (4)
29.29%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
89.84%
Max Revenue beat (4)
232.25%
Min Revenue beat (4)
-4.81%
Analysis
In the last 4 quarters, ALPN has consistently beaten EPS estimates in all releases
ALPN has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, ALPN has beaten the EPS estimates by 56.9% on average.
In the last 4 quarters, ALPN has beaten the revenue estimates by 89.8% on average.
Related analysis
ALPINE IMMUNE SCIENCES INC / ALPN Earnings FAQ
Can you provide information on whether ALPINE IMMUNE SCIENCES INC beat earnings estimates in the last quarter?
ALPINE IMMUNE SCIENCES INC (ALPN) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does ALPN stock beat earnings estimates?
In the last 4 quarters, ALPINE IMMUNE SCIENCES INC (ALPN) has beaten EPS estimates in 4 out of 4 releases.